Search Results - "SHITARA, Kenya"

Engineered therapeutic antibodies with improved effector functions by Kubota, Tsuguo, Niwa, Rinpei, Satoh, Mitsuo, Akinaga, Shiro, Shitara, Kenya, Hanai, Nobuo

“…In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of…”
Get full text

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies by Satoh, Mitsuo, Iida, Shigeru, Shitara, Kenya

“…Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of…”
Get more information

Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1 by Matsumiya, Shigeki, Yamaguchi, Yoshiki, Saito, Jun-ichi, Nagano, Mayumi, Sasakawa, Hiroaki, Otaki, Shizuo, Satoh, Mitsuo, Shitara, Kenya, Kato, Koichi

“…Removal of the fucose residue from the oligosaccharides attached to Asn297 of human immunoglobulin G1 (IgG1) results in a significant enhancement of…”
Get full text

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity by Shinkawa, Toyohide, Nakamura, Kazuyasu, Yamane, Naoko, Shoji-Hosaka, Emi, Kanda, Yutaka, Sakurada, Mikiko, Uchida, Kazuhisa, Anazawa, Hideharu, Satoh, Mitsuo, Yamasaki, Motoo, Hanai, Nobuo, Shitara, Kenya

“…An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines…”
Get full text

Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa by IIDA, Shigeru, MISAKA, Hirofumi, INOUE, Miho, SHIBATA, Mami, NAKANO, Ryosuke, YAMANE-OHNUKI, Naoko, WAKITANI, Masako, YANO, Keiichi, SHITARA, Kenya, SATOH, Mitsuo

“…Purpose: Recent studies have revealed that fucosylated therapeutic IgG1s need high concentrations to compensate for FcγRIIIa-competitive inhibition of…”
Get full text

Engineered anti‐CD20 antibodies with enhanced complement‐activating capacity mediate potent anti‐lymphoma activity by Natsume, Akito, Shimizu‐Yokoyama, Yukiko, Satoh, Mitsuo, Shitara, Kenya, Niwa, Rinpei

“…One of the major issues in current antibody therapy is insufficient efficacy. Various biological factors relating to the host’s immune system or tumor cells…”
Get full text

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood by Iida, Shigeru, Kuni-Kamochi, Reiko, Mori, Katsuhiro, Misaka, Hirofumi, Inoue, Miho, Okazaki, Akira, Shitara, Kenya, Satoh, Mitsuo

“…Antibody-dependent cellular cytotoxicity (ADCC) has recently been identified as one of the critical mechanisms underlying the clinical efficacy of therapeutic…”
Get full text

Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism by Niwa, Rinpei, Hatanaka, Shigeki, Shoji-Hosaka, Emi, Sakurada, Mikiko, Kobayashi, Yukari, Uehara, Aya, Yokoi, Haruhiko, Nakamura, Kazuyasu, Shitara, Kenya

“…Purpose: The most common polymorphic variant of Fcγ receptor type IIIa (FcγRIIIa), FcγRIIIa-158F, has been associated with inferior clinical responses to…”
Get full text

Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy by Yamaguchi, Yoshiki, Nishimura, Mamiko, Nagano, Mayumi, Yagi, Hirokazu, Sasakawa, Hiroaki, Uchida, Kazuhisa, Shitara, Kenya, Kato, Koichi

“…The Fc portion of immunoglobulin G (IgG) expresses the biantennary complex type oligosaccharides at Asn297 of the C H2 domain of each heavy chain with…”
Get full text

Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC by Imai-Nishiya, Harue, Mori, Katsuhiro, Inoue, Miho, Wakitani, Masako, Iida, Shigeru, Shitara, Kenya, Satoh, Mitsuo

“…BACKGROUND: Antibody-dependent cellular cytotoxicity (ADCC) is greatly enhanced by the absence of the core fucose of oligosaccharides attached to the Fc, and…”
Get full text

Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans by Sawano, Asako, Iwai, Shinobu, Sakurai, Yoshiko, Ito, Mikito, Shitara, Kenya, Nakahata, Tatsutoshi, Shibuya, Masabumi

“…Flt-1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1), is a high-affinity tyrosine kinase receptor for VEGF and is expressed almost…”
Get full text

Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density by NIWA, Rinpei, SAKURADA, Mikiko, KOBAYASHI, Yukari, UEHARA, Aya, MATSUSHIMA, Kouji, UEDA, Ryuzo, NAKAMURA, Kazuyasu, SHITARA, Kenya

“…Purpose: Recent studies have revealed that fucose removal from the oligosaccharides of human IgG1 antibodies results in a significant enhancement of…”
Get full text

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells by KANNO, S, ODA, N, ABE, M, TERAI, Y, ITO, M, SHITARA, K, TABAYASHI, K, SHIBUYA, M, SATO, Y

“…Vascular endothelial growth factor (VEGF) is a principal regulator of vasculogenesis and angiogenesis. VEGF expresses its effects by binding to two VEGF…”
Get full text

A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients by SUZUKI, Eiji, NIWA, Rinpei, TOI, Masakazu, SAJI, Shigehira, MUTA, Mariko, HIROSE, Makiko, IIDA, Shigeru, SHIOTSU, Yukimasa, SATOH, Mitsuo, SHITARA, Kenya, KONDO, Masahide

“…Purpose: Removal of fucose residues from the oligosaccharides of human antibody is a powerful approach to enhance antibody-dependent cellular cytotoxicity…”
Get full text

Potelligent Antibodies as Next Generation Therapeutic Antibodies by SHITARA, Kenya

“…Antibody-dependent cellular cytotoxicity (ADCC), a lytic attack on antibody-targeted cells, is triggered upon binding of lymphocyte receptors (FcγRs) to the…”
Get full text

Establishment of a GDP-mannose 4,6-dehydratase ( GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics by Kanda, Yutaka, Imai-Nishiya, Harue, Kuni-Kamochi, Reiko, Mori, Katsuhiro, Inoue, Miho, Kitajima-Miyama, Kazuko, Okazaki, Akira, Iida, Shigeru, Shitara, Kenya, Satoh, Mitsuo

“…Currently, removal of core fucose from the Fc oligosaccharides of therapeutic antibodies is widely recognized as being of great importance for the effector…”
Get full text

The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma by ISHIDA, Takashi, IIDA, Shinsuke, AKINAGA, Shiro, TAKAHASHI, Toshitada, UTSUNOMIYA, Atae, UEDA, Ryuzo, AKATSUKA, Yoshiki, ISHII, Toshihiko, MIYAZAKI, Mikinori, KOMATSU, Hirokazu, INAGAKI, Hiroshi, OKADA, Noriko, FUJITA, Teizo, SHITARA, Kenya

“…Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm with dismal prognosis, and no optimal therapy has been developed. We tested the…”
Get full text

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA by Mori, Katsuhiro, Kuni-Kamochi, Reiko, Yamane-Ohnuki, Naoko, Wakitani, Masako, Yamano, Kazuya, Imai, Harue, Kanda, Yutaka, Niwa, Rinpei, Iida, Shigeru, Uchida, Kazuhisa, Shitara, Kenya, Satoh, Mitsuo

“…We explored the possibility of converting established antibody‐producing cells to cells producing high antibody‐dependent cellular cytotoxicity (ADCC)…”
Get full text

RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy by Kawata, Hirotoshi, Shimada, Naoki, Kamiakito, Tomoko, Komatsu, Kenji, Morita, Tatsuo, Ota, Toshio, Obayashi, Masaya, Shitara, Kenya, Tanaka, Akira

“…BACKGROUND Endocrine resistance is a critical issue in managing patients with prostate cancer. This study is undertaken to search for a potential molecular…”
Get full text

Mouse-Human Chimeric Anti-Tn IgG1 Induced Anti-tumor Activity against Jurkat Cells in Vitro and in Vivo by Ando, Hiroshi, Matsushita, Takefumi, Wakitani, Masako, Sato, Takashi, Kodama-Nishida, Sachiko, Shibata, Kenji, Shitara, Kenya, Ohta, So

“…Tn-antigen (α-N-acetyl-galactosamine(GalNAc)-Ser/Thr) is a cancer-associated carbohydrate antigen expressed in various epithelial and hematological cancers,…”
Get full text